With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.655225-01-7,tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
655225-01-7, Preparation 7.3N-Methyl-N-[2-(piperazin-1 -yl)ethyl]acetamide ditrifluoroacetate. 0.341 g of 60percent NaH in oil is added to a solution of 0.748 g of N- methylacetamide in 80 ml of THF and stirred for 10 minutes at RT. Then 2 g of fe/f-butyl 4-(2-bromoethyl)piperazinecarboxylate is added and stirred for 16 hours at RT. Water is added to the reaction mixture, it is decanted and the organic solvent is evaporated under vacuum. The residue is dissolved in DCM, filtered through a Chem Elut.(R). cartridge, eluting with DCM and the solvents are evaporated under vacuum. The residue is purified by preparative HPLC and a white solid is obtained. The solid is dissolved in 5 ml of DCM, 1 .2 ml of TFA is added and it is stirred for 16 hours at RT. The reaction mixture is diluted by adding 100 ml of toluene and the solvents are concentrated under vacuum.1 .5 g of the expected compound is obtained.
The synthetic route of 655225-01-7 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; SANOFI; BADORC, Alain; BOLDRON, Christophe; DELESQUE, Nathalie; FOSSEY, Valerie; LASSALLE, Gilbert; YVON, Xavier; WO2012/146318; (2012); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics